甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效观察.docVIP

精品论文 参考文献 甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效观察 郭菊秋 　　河北省唐山市古治区医院 063103 　　摘要：目的 探讨甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭患者的临床效果。方法 将我院收治的92例老年重症心力衰竭的患者分为常规抗心力衰竭治疗的对照组46例，和在对照组常规治疗基础上口服厄贝沙坦氢氯噻嗪联合甲状腺素进行治疗的观察组46例，两组患者分别治疗3~4周，观察治疗前后两组患者的左室射血分数、心功能分级、血清三碘甲状腺圆原氨酸等检查指标和临床症状。结果 治疗后观察组患者T3、T4和LVEF水平、临床效果显著高于治疗前和对照组治疗后，NYHA评分显著低于治疗前和对照组治疗后，差异具有统计学意义（P＜0.05）。结论 使用甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症CHF时效果显著，可在临床范围内推广使用。 　　关键词：甲状腺素；厄贝沙坦氢氯噻嗪；老年重症心力衰竭；临床效果 　　【Abstract】 Objective To explore the thyroxine joint irbesartan and hydrochlorothiazide effect of clinical treatment in elderly patients with severe heart failure.Methods Our hospital 92 cases of elderly patients with severe heart failure were divided into normal control group 46 cases of heart failure treatment，and the control group on the basis of oral irbesartan and hydrochlorothiazide joint thyroxine treatment of 46 cases of observation group，two groups of patients with treatment of 3 ~ 4 weeks respectively，were observed before and after treatment of two groups of patients with left ventricular ejection fraction and grade of cardiac function，serum thyroid round three iodine glycine and clinical effect.Results After treatment，the observation group of patients with T3，T4 and LVEF level，clinical effect is significantly higher than before and the control group after treatment，the NYHA score was significantly lower than before and the control group after treatment，the difference is statistically significant（P lt; 0.05）.Conclusion Using thyroxine joint irbesartan and hydrochlorothiazide treating senile severe CHF effect significantly，can be used within the scope of clinical promotion. 　　【Key words】 Thyroxine；Irbesartan and hydrochlorothiazide；Senile severe heart failure；Clinical effect 　　心力衰竭（Congestive Hearts Failure，CHF）是心脏收缩或舒张功能发生障碍后静脉回心血量不能充分排出心脏，引起静脉系统血液淤积，动脉系统血液灌注不足引发的心脏循环障碍症候群。CHF在临床上比较常见，其发病率和患者年龄呈现出正相关的趋势，老年患者在临床治疗时存在很大的风险性，患者容易伴发急性呼吸系统衰竭，如果抢救不及时会引起死亡[1]。大量临床研究证实这类老年患者在心脏受损的同时机体内神经-内分泌也出现一系列的变化，心力衰竭时甲状腺素的含量降低，因此给与甲状腺素治疗CHF具有一定的效果。本研究旨在探讨甲状腺素联合厄